CD274 and breast cancer: The small sample size (n = 36) and highly heterogeneous population (e.g., TN and HR + BC, different previous lines of treatment) represent a major limitation at this point; therefore, our results should be considered cautiously, especially when the IMpassion-130 and KEYNOTE-522 trials have reported favorable results in PD-L1 enriched populations.